SAGE

Sage Therapeutics Inc

53.74
1.81 (3.49%)
Company Name Stock Ticker Symbol Market Type
Sage Therapeutics Inc SAGE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.81 3.49% 53.74 20:00:00
Open Price Low Price High Price Close Price Prev Close
52.06 52.06 54.35 53.74 51.93
more quote information »

Recent News

Date Time Source Heading
6/05/202306:30BWSage Therapeutics to Present at the Goldman Sachs 44th..
5/11/202308:59EDGARStatement of Changes in Beneficial Ownership (4)
5/03/202306:30BWSage Therapeutics to Present at Upcoming May Investor..
5/02/202306:46EDGARCurrent Report Filing (8-k)
5/02/202306:30BWSage Therapeutics Announces First Quarter 2023 Financial..
4/27/202316:17EDGARAnnual Report to Security Holders (ars)
4/27/202316:15EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
4/18/202306:30BWSage Therapeutics to Report First Quarter 2023 Financial..
3/22/202306:30BWSage Therapeutics to Present at the Stifel 2023 CNS Days
3/16/202306:38EDGARCurrent Report Filing (8-k)
3/16/202306:30BWSage Therapeutics Appoints Jessica Federer to Board of..
3/08/202306:30BWSage Therapeutics and Biogen Share Update on FDA Advisory..
2/28/202316:05BWSage Therapeutics to Present at the Cowen 43rd Annual Health..
2/23/202318:03EDGARStatement of Changes in Beneficial Ownership (4)
2/22/202306:30BWSage Therapeutics Announces European Medicines Agency..
2/16/202306:30BWSage Therapeutics Announces Fourth Quarter and Full Year..
2/15/202316:47EDGARStatement of Changes in Beneficial Ownership (4)
2/15/202316:47EDGARStatement of Changes in Beneficial Ownership (4)
2/15/202316:47EDGARStatement of Changes in Beneficial Ownership (4)
2/10/202316:43EDGARStatement of Changes in Beneficial Ownership (4)
2/09/202312:35EDGARAmended Statement of Ownership (sc 13g/a)
2/09/202312:23EDGARAmended Statement of Ownership (sc 13g/a)
2/07/202316:12EDGARStatement of Changes in Beneficial Ownership (4)
2/07/202316:12EDGARStatement of Changes in Beneficial Ownership (4)
2/07/202316:11EDGARStatement of Changes in Beneficial Ownership (4)
2/06/202314:59EDGARSchedule 13g
(sc 13g/a)
2/06/202307:18DJNBiogen, Sage Get FDA Priority Review of Zuranolone
2/06/202306:46EDGARCurrent Report Filing (8-k)
2/06/202306:30BWSage Therapeutics and Biogen Announce FDA Accepts Filing of..
2/03/202312:14EDGARStatement of Ownership (sc 13g)
2/02/202306:30BWSage Therapeutics to Report Fourth Quarter and Full Year..
1/11/202316:03EDGARStatement of Changes in Beneficial Ownership (4)
1/08/202312:00BWSage Therapeutics to Provide Update on 2023 Key Initiatives..
1/05/202316:30EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202316:30EDGARStatement of Changes in Beneficial Ownership (4)
1/03/202306:30BWSage Therapeutics to Present at the 41st Annual J.P. Morgan..
12/08/202206:55TRMNH.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics..
12/06/202219:35TRMNMizuho Securities Keeps Their Hold Rating on SAGE..
12/06/202212:05TRMNSAGE Therapeutics (SAGE) Receives a Buy from Needham
12/06/202206:51EDGARCurrent Report Filing (8-k)
12/06/202206:30BWSage Therapeutics and Biogen Complete Rolling Submission of..
11/23/202206:30BWSage Therapeutics to Present at the Piper Sandler 34th..
11/22/202207:00BWSage Therapeutics and Biogen to Host Investor Webcast on..
11/21/202211:42TRMNAnalysts Offer Insights on Healthcare Companies: SAGE..
11/16/202203:42TRMNSage Therapeutics (NASDAQ:SAGE) Rises as CEO Loads Up Stock
11/15/202216:05EDGARStatement of Changes in Beneficial Ownership (4)
11/11/202218:05TRMNMizuho Securities Sticks to Their Hold Rating for SAGE..
11/09/202206:30BWSage Therapeutics to Present at the Stifel 2022 Healthcare..
11/09/202205:15TRMNNeedham Remains a Buy on SAGE Therapeutics (SAGE)
11/08/202207:22EDGARQuarterly Report (10-q)